NasdaqGS:ABCLLife Sciences
A Look At AbCellera Biologics (ABCL) Valuation After Its Planned ABCL635 Phase 1 Data Update
AbCellera Biologics (ABCL) has drawn fresh attention after announcing plans to share interim Phase 1 data for its menopause therapy candidate ABCL635 during its first quarter 2026 earnings call on May 11.
See our latest analysis for AbCellera Biologics.
The recent ABCL635 update comes after a mixed stretch for the stock, with a 21.07% 1 month share price return and 18.95% year to date share price return contrasting with a 12.07% 3 month decline. The 61.26% 1 year total shareholder return...